Researchers have identified CD44+ monocytes as key drivers of inflammation in bronchopulmonary dysplasia (BPD) in very premature infants, tying a specific immune cell phenotype to the hyperinflammatory biology of the disease. The work points to a more targeted immunology frame for BPD—where patient-level risk is high and current interventions often lack precision against underlying inflammatory mechanisms.